The results of grouping of the Ukrainian regions by epidemiological indicators for lung and bronchial cancer as an important component in the development of rational ways to finance the pharmaceutical component of state programs to combat cancer

Authors

DOI:

https://doi.org/10.24959/sphhcj.22.243

Keywords:

Incidence of lung and bronchial cancer; lung cancer; bronchial cancer; mortality from lung cancer; mortality from bronchial cancer; oncoepidemiology.

Abstract

Aim. To group the regions of Ukraine by the indicators of morbidity and mortality of the population from lung and bronchial cancer and identify the areas that require public attention and resource support from the state for the purpose of early detection of these pathologies and the organization of effective pharmaceutical provision of cancer patients.

Materials and methods. The data of the National Cancer Register for 2014-2019 by indicators of morbidity and mortality of the population from lung and bronchial cancer were analyzed. Both general theoretical (historical, analytical-comparative, system, graphical, logical, hypothetical-deductive) and applied (epidemiological, mathematical-statistical) research methods were used.

Results. It was found that the average values of morbidity and mortality of the population from lung and bronchial cancer in Ukraine in accordance with the sex and age structure were 66.78 ± 0.05 and 53.67 ± 0.03 per 100 thousand populations, respectively. There was a significant fluctuation in these indicators by regions. The lowest and highest values of morbidity and mortality were observed in the same regions, namely in Kyiv and the Kherson region, respectively. Thus, in the Kherson region, the average incidence of lung and bronchial cancer was 1.8 times, and the death rate was 1.9 times higher than in Kyiv. It was proven that most regions (45.84 % of their total number) of the country were included in the groups with an unfavorable (3 regions and Ukraine as a whole) and extremely unfavorable state of development of the oncoepidemiological situation (7 regions of the country). Concern about the high mortality rate from lung and bronchial cancer is caused by the situation that has developed in the Kharkiv, Khmelnytskyi and Mykolaiv regions. We believe that in the group of regions with an extremely unfavorable state of development of the oncoepidemiological situation for lung and bronchial cancer, special attention in the direction of early detection and effective medical and pharmaceutical support should be paid to areas with the highest rates of morbidity and mortality of patients. These are Dnipropetrovsk, Zaporizhia, Kirovohrad and Kherson regions.

Conclusions. The presence of significant fluctuations in morbidity and mortality rates of the population from lung and bronchial cancer in the regions of the country necessitates the development and implementation of regional programs for the early detection of these pathologies and the provision of cancer patients with affordable and effective anticancer drugs in accordance with the existing resource provision at the regional and local community level.

Author Biographies

H. L. Panfilova, National University of Pharmacy of the Ministry of Health of Ukraine

Doctor of Pharmacy (Dr. habil.), professor of the Department of Organization and Economics of Pharmacy,
National University of Pharmacy

Yu. Yu. Pulnyi, National University of Pharmacy of the Ministry of Health of Ukraine

Рostgraduate student of the Department of Organization and Economics of Pharmacy, National University
of Pharmacy

L. V. Tereshchenko, National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Social Pharmacy, National
University of Pharmacy

V. M. Chernukha, National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Organization and Economics
of Pharmacy, National University of Pharmacy

G. M. Iurchenko , National University of Pharmacy of the Ministry of Health of Ukraine

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Organization and Economics of
Pharmacy, National University of Pharmacy

References

National Cancer Registry of Ukraine: short description of the database as of January, 2020. Cancer in Ukraine 2018-2019. Available at: http://www.ncru.inf.ua/publications/.

Onkolohiia–2021: sohodennia ta perspektyvy rozvytku. (2021). Shchotyzhnevyk «Apteka», 5 (1276). Available at: https://www.apteka.ua/article/582977.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021). Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 71(3), 209-249. doi: 10.3322/caac.21660.

Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh, J.W.W., Comber, H.et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer, 49 (6), 1374–1403. doi: https://doi.org/10.1016/j.ejca.2012.12.027.

Smorodska, O. M., Moskalenko, Yu. V., Vynnychenko, O. I., Pryvalova, A. O., Kostiuchenko, V. V. (2021). Art of Medicine, 2 (18), 116-123. doi: https://doi.org/10.21802/artm.2021.2.18.116.

Bade, B. C., Dela Cruz, C. S. (2020). Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clinics in Chest Medicine, 41 (1), 1–24. doi: https://doi.org/10.1016/j.ccm.2019.10.001.

Gouvinhas, C., De Mello, R. A., Oliveira, D., Castro-Lopes, J. M., Castelo-Branco, P., Dos Santos, R. S. et al. (2018). Lung cancer: a brief review of epidemiology and screening. Future Oncol., 14 (6), 567-575. doi: 10.2217/fon-2017-0486.

Barta, J. A., Powell, C. A., Wisnivesky, J. P. (2019). Global Epidemiology of Lung Cancer. Annals of Global Health, 85 (1), 8. doi: http://doi.org/10.5334/aogh.2419.

Khajedaluee, M., Dadgarmoghaddam, M., Saeedi, R., IzadiMood, Z., et al. (2014). Mortality, morbidity, survival, and burden of top 9 cancers in a developing country. Raz Int J Med, 2, 1–9. doi: https://doi.org/10.5812/rijm.20073.

Thun, M. J., Henley, S. J., Travis, W. D. (2018). Cancer Epidemiology and Prevention. (4th ed.). Oxford University Press, 519-578. doi: 10.1093/oso/9780190238667.001.0001.

Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh, J.W.W., Comber, H.et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer, 49 (6), 1374–1403. doi: https://doi.org/10.1016/j.ejca.2012.12.027.

Nasim, F., Sabath, B. F., Eapen, G. A.(2019). Lung Cancer. Med Clin North Am., 103 (3), 463-473. DOI:10.1016/j.mcna.2018.12.006.

Zhong, Y. J., Wen, Y. F., Wong, H. M., Yin, G., Lin, R., Yang, Sh. Y. (2019). Trends and patterns of disparities in burden of lung cancer in the United States, 1974–2015. Front Oncol. doi: https://doi.org/10.3389/fonc.2019.00404.

Turner, M. C., Andersen, Z. J., Baccarelli, A., Diver, W. R., Gapstur, S. M., Pope, C. A. et al. (2020). Outdoor air pollution and cancer: an overview of the current evidence and public health recommendations. CA Cancer J Clin., 70, 460-479. doi: https://doi.org/10.3322/caac.21632.

Romaniv, M. P. (2017). Visnyk naukovykh doslidzhen, 1, 85-90.

Jemal, A., Miller, K. D., Ma, J., Siegel, R. L., Fedewa, S. A., Islami, F. et al. (2018). Higher lung cancer incidence in young women than young men in the United States. N Engl J Med., 378, 1999-2009. DOI: https://doi.org/10.1056/NEJMoa1715907.

Fidler-Benaoudia, M. M., Torre, L. A., Bray, F., Ferlay, J., Jemal, A. (2020). Lung cancer incidence in young women vs. young men: a systematic analysis in 40 countries. Int J Cancer, 147 (3), 811-819. doi: https://doi.org/10.1002/ijc.32809.

Gray, E. P., Teare, M. D., Stevens, J., Archer, R. (2016). Risk prediction models for lung cancer: a systematic review. Clin Lung Cancer, 17 (2), 95–106. doi: https://doi.org/10.1016/j.cllc.2015.11.007.

Ferreccio, C., Yuan, Y., Calle, J., Benítez, H., Parra, R. L., Acevedo, J. al. (2013). Arsenic, tobacco smoke, and occupation: associations of multiple agents with lung and bladder cancer. Epidemiology, 24 (6), 898–905. doi: https://doi.org/10.1097/EDE.0b013e31829e3e03.

Voitko, O. V., Omelchuk, S. T., Ostapchuk, Yu. M. (2009). Onkolohiia, 11 (4), 257-262.

Fang, J.-Q. (Ed.). (2017). Handbook of Medical Statistics. China: Sun Yat-Sen University, 852. doi: https://doi.org/10.1142/10259.

Published

2022-05-26

Issue

Section

Health organization